UA76969C2 - Lactams and their pharmaceutical use - Google Patents

Lactams and their pharmaceutical use Download PDF

Info

Publication number
UA76969C2
UA76969C2 UA2003055026A UA2003055026A UA76969C2 UA 76969 C2 UA76969 C2 UA 76969C2 UA 2003055026 A UA2003055026 A UA 2003055026A UA 2003055026 A UA2003055026 A UA 2003055026A UA 76969 C2 UA76969 C2 UA 76969C2
Authority
UA
Ukraine
Prior art keywords
substituent
group
acyl
alkyl
carbamoyl
Prior art date
Application number
UA2003055026A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of UA76969C2 publication Critical patent/UA76969C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
UA2003055026A 2000-12-01 2001-11-29 Lactams and their pharmaceutical use UA76969C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01
PCT/JP2001/010435 WO2002044180A1 (en) 2000-12-01 2001-11-29 Lactam compounds and medicinal use thereof

Publications (1)

Publication Number Publication Date
UA76969C2 true UA76969C2 (en) 2006-10-16

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003055026A UA76969C2 (en) 2000-12-01 2001-11-29 Lactams and their pharmaceutical use

Country Status (26)

Country Link
US (3) US7153850B2 (cs)
EP (1) EP1346993B1 (cs)
JP (2) JP3826400B2 (cs)
KR (1) KR100826818B1 (cs)
CN (2) CN100577651C (cs)
AT (1) ATE446297T1 (cs)
AU (3) AU2002218502B2 (cs)
BG (1) BG107857A (cs)
BR (1) BR0115852A (cs)
CA (1) CA2430124C (cs)
CZ (1) CZ20031520A3 (cs)
DE (1) DE60140270D1 (cs)
ES (1) ES2331299T3 (cs)
HU (1) HUP0400806A3 (cs)
IL (1) IL156158A0 (cs)
MX (1) MXPA03004876A (cs)
NO (1) NO325401B1 (cs)
NZ (1) NZ526164A (cs)
PL (1) PL362835A1 (cs)
RU (1) RU2287530C2 (cs)
SK (1) SK6582003A3 (cs)
TW (1) TWI241302B (cs)
UA (1) UA76969C2 (cs)
WO (1) WO2002044180A1 (cs)
YU (1) YU42603A (cs)
ZA (1) ZA200304100B (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100577651C (zh) * 2000-12-01 2010-01-06 味之素株式会社 内酰胺化合物及其药物用途
BRPI0407303A (pt) * 2003-02-07 2006-02-07 Ajinomoto Kk Composição farmacêutica
CA2544310A1 (en) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
EP1707567A4 (en) * 2004-01-14 2009-08-19 Ajinomoto Kk NEW FUSED CYCLE COMPOUND
DK1802625T3 (da) * 2004-10-13 2008-09-01 Hoffmann La Roche Disubstituerede pyrazolobenzodiazepiner der er nyttige som inhibitorer af CDK2 og angiogenese og til behandling af bryst-, tyktarms-, lunge- og prostatacancer
CN101166742B (zh) * 2005-04-28 2011-07-13 味之素株式会社 新型内酰胺化合物
JP5672699B2 (ja) 2007-04-11 2015-02-18 味の素株式会社 血糖降下作用化合物のスクリーニング法
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008136393A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
US20170369494A1 (en) * 2014-12-22 2017-12-28 Ea Pharma Co., Ltd. Drug for treating disorders of corneal epithelium
WO2017127306A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
SG11202106694YA (en) * 2019-01-23 2021-07-29 Glycolysis Biomed Co Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
JP2001512120A (ja) 1997-07-30 2001-08-21 アメリカン・ホーム・プロダクツ・コーポレイション 三環系バソプレシンアゴニスト
JP4204657B2 (ja) 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
CN100577651C (zh) * 2000-12-01 2010-01-06 味之素株式会社 内酰胺化合物及其药物用途
BRPI0407303A (pt) 2003-02-07 2006-02-07 Ajinomoto Kk Composição farmacêutica

Also Published As

Publication number Publication date
US7153850B2 (en) 2006-12-26
ES2331299T3 (es) 2009-12-29
WO2002044180A1 (en) 2002-06-06
CA2430124A1 (en) 2002-06-06
DE60140270D1 (de) 2009-12-03
AU1850202A (en) 2002-06-11
EP1346993A4 (en) 2005-12-21
JPWO2002044180A1 (ja) 2004-04-02
KR100826818B1 (ko) 2008-05-02
JP3826400B2 (ja) 2006-09-27
NZ526164A (en) 2004-09-24
NO325401B1 (no) 2008-04-21
EP1346993A1 (en) 2003-09-24
JP2006213732A (ja) 2006-08-17
EP1346993B1 (en) 2009-10-21
CN1487940A (zh) 2004-04-07
ATE446297T1 (de) 2009-11-15
HUP0400806A3 (en) 2007-11-28
NO20032439D0 (no) 2003-05-28
AU2002218502B2 (en) 2006-09-21
TWI241302B (en) 2005-10-11
US20080096862A1 (en) 2008-04-24
CZ20031520A3 (cs) 2003-10-15
RU2287530C2 (ru) 2006-11-20
US7632830B2 (en) 2009-12-15
AU2006241377A1 (en) 2006-12-14
CA2430124C (en) 2011-01-11
MXPA03004876A (es) 2004-01-27
SK6582003A3 (en) 2003-09-11
BG107857A (bg) 2004-06-30
KR20030051893A (ko) 2003-06-25
NO20032439L (no) 2003-07-18
US7326701B2 (en) 2008-02-05
US20060189597A1 (en) 2006-08-24
PL362835A1 (en) 2004-11-02
YU42603A (sh) 2006-03-03
AU2006241377B2 (en) 2009-01-08
ZA200304100B (en) 2004-08-22
CN1269818C (zh) 2006-08-16
CN1911915A (zh) 2007-02-14
JP4505753B2 (ja) 2010-07-21
CN100577651C (zh) 2010-01-06
IL156158A0 (en) 2003-12-23
BR0115852A (pt) 2003-12-23
US20040048847A1 (en) 2004-03-11
HUP0400806A2 (hu) 2004-07-28

Similar Documents

Publication Publication Date Title
EP3307262B1 (en) Compounds for use in treating neuromuscular disorders
TW215055B (cs)
EP4349840A2 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
EP3615019B1 (en) Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
KR20220082092A (ko) 화합물
UA75660C2 (en) Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
UA124026C2 (uk) Фенільні похідні
JP2025010154A (ja) 線維症及び炎症の処置のための組成物
UA76977C2 (en) Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
KR20030016376A (ko) 남성 성기능 장애의 치료
TW201028380A (en) C5aR antagonists
UA80162C2 (en) Novel alkyne compounds having an mch antagonistic effect and medicaments containing these compounds
KR20120087878A (ko) 1,3-프로판디설포닉 애시드의 수송을 위한 방법, 화합물 및 조성물
WO2012118562A1 (en) Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
ES2910049T3 (es) Moduladores heterocíclicos de la síntesis de lípidos
ES2882175T3 (es) Compuestos para su uso en el tratamiento de la hipertensión pulmonar
CN116120314A (zh) 用于调节毛发生长的组合物和方法
JPH02503794A (ja) アルツハイマー病の治療のための化合物
RU2233278C2 (ru) Пиримидиновые соединения, способ их получения и фармацевтическая композиция
HUP0202938A2 (hu) N-aril-2-(szulfonil-amino)-benzamidok mint foszfát-transzport inhibitorok és ezeket tartalmazó gyógyszerkészítmények
TW200304817A (en) Chemical compounds
US20250090530A1 (en) Combinations for the treatment of cancer
NO325401B1 (no) Laktamforbindelser, anvendelse av slike samt farmasoytisk preparat inneholdende nevnte laktamforbindelser
SA95160293B1 (ar) مشتقات حمض اميني حلقي cyclic amiono acid لها نشاط تثبيط انزيم ACE وNEP
HUP0302234A2 (hu) Foszfát-transzport inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk